Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies

References

• Spillantini MG, Goedert M, Crowther RA, et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A. 1997;94(8):4113–4118. doi: 10.1073/pnas.94.8.4113
   PubMed Web of Science ®Google Scholar
• Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122(2):137–153. doi: 10.1007/s00401-011-0839-6
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609–622. doi: 10.1016/S1474-4422(13)70090-5
   PubMed Web of Science ®Google Scholar
• Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126(Pt 3):238–292. doi: 10.1016/j.brainresbull.2016.08.018
   PubMed Web of Science ®Google Scholar
• Josephs KA. Current understanding of neurodegenerative diseases associated with the protein tau. Mayo Clin Proc. 2017;92(8):1291–1303. doi: 10.1016/j.mayocp.2017.04.016
   PubMed Web of Science ®Google Scholar
• Sexton C, Snyder H, Beher D, et al. Current directions in tau research: Highlights from Tau 2020. Alzheimers Dement. 2022;18(5):988–1007. doi: 10.1002/alz.12452
   PubMed Web of Science ®Google Scholar
• Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41(1):3–23. doi: 10.1111/nan.12208
   PubMed Web of Science ®Google Scholar
• Panza F, Imbimbo BP, Lozupone M, et al. Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Rev Neurother. 2019;19(5):397–408. doi: 10.1080/14737175.2019.1606715
   PubMed Web of Science ®Google Scholar
• Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4):360–370. doi: 10.1001/jama.2017.8334
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Tolnay M, Love S, et al. Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia. Acta Neuropathol. 1999;97(6):585–594. doi: 10.1007/s004010051034
   PubMed Web of Science ®Google Scholar
• Bussiere T, Hof PR, Mailliot C, et al. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol. 1999;97(3):221–230. doi: 10.1007/s004010050978
   PubMed Web of Science ®Google Scholar
• Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755–766. doi: 10.1007/s00401-014-1349-0
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Ferrer I, Grinberg LT, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87–102. doi: 10.1007/s00401-015-1509-x
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett. 1987;76(1):124–127. doi: 10.1016/0304-3940(87)90204-7
   PubMed Web of Science ®Google Scholar
• Duyckaerts C, Braak H, Brion J-P, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129(5):749–756. doi: 10.1007/s00401-015-1390-7
   PubMed Web of Science ®Google Scholar
• Jack CR, Knopman DS, Chételat G3 G, et al. Suspected non Alzheimer disease pathophysiology – concept and controversy. Nat Rev Neurol. 2016;12(2):117–124. doi: 10.1038/nrneurol.2015.251
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Robinson JL, Xie SX, et al. Evaluating the patterns of aging-related tau astrogliopathy unravels novel insights into brain aging and neurodegenerative diseases. J Neuropathol Exp Neurol. 2017;76(4):270–288. doi: 10.1093/jnen/nlx007
   PubMed Web of Science ®Google Scholar
• Ling H, Kovacs GG, Vonsattel JPG, et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain. 2016;139(Pt 12):3237–3252. doi: 10.1093/brain/aww256
   PubMedGoogle Scholar
• Coughlin D, Irwin DJ. Emerging diagnostic and therapeutic strategies for tauopathies. Curr Neurol Neurosci Rep. 2017;17(9):72. doi: 10.1007/s11910-017-0779-1
   PubMed Web of Science ®Google Scholar
• Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016;22(Suppl 1):S29–S33. doi: 10.1016/j.parkreldis.2015.09.020
   PubMed Web of Science ®Google Scholar
• Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5‘- splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393(6686):702–705. doi: 10.1038/31508
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2020;11981:1–4.
   Google Scholar
• Panza F, Lozupone M, Seripa D, et al. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 2020;16(4):213–228. doi: 10.1038/s41582-020-0330-x
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–2477. doi: 10.1093/brain/awr179
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–1014. doi: 10.1212/WNL.0b013e31821103e6
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496–503. doi: 10.1212/WNL.0b013e31827f0fd1
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864. doi: 10.1002/mds.26987
   PubMed Web of Science ®Google Scholar
• Neve RL, Harris P, Kosik KS, et al. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 1986;387(3):271–280. doi: 10.1016/0169-328X(86)90033-1
   PubMed Web of Science ®Google Scholar
• LoPresti P, Szuchet S, Papasozomenos SC, et al. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A. 1995;92(22):10369–10373. doi: 10.1073/pnas.92.22.10369
   PubMed Web of Science ®Google Scholar
• Jeganathan S, von Bergen M, Mandelkow EM, et al. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry. 2008;47(40):10526–10539. doi: 10.1021/bi800783d
   PubMed Web of Science ®Google Scholar
• Wang JZ, Xia YY, Grundke-Iqbal I, et al. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis. 2013;33(Suppl s1):S123–39. doi: 10.3233/JAD-2012-129031
   PubMedGoogle Scholar
• Boyko S, Qi X, Chen TH, et al. Liquid-liquid phase separation of tau protein: The crucial role of electrostatic interactions. J Biol Chem. 2019;294(29):11054–11059. doi: 10.1074/jbc.AC119.009198
   PubMed Web of Science ®Google Scholar
• Ramesh M, Balachandra C, Baruah P, et al. Cyclic dipeptide-based small molecules modulate zinc-mediated liquid–liquid phase separation of tau. J Pept Sci. 2022;29(5):e3465. doi: 10.1002/psc.3465
   PubMed Web of Science ®Google Scholar
• Holmes BB, Diamond MI. Prion-like properties of tau protein: the importance of extracellular tau as a therapeutic target. J Biol Chem. 2014;289(29):19855–19861. doi: 10.1074/jbc.R114.549295
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3(4):519–526. doi: 10.1016/0896-6273(89)90210-9
   PubMed Web of Science ®Google Scholar
• Fischer I, Baas PW. Resurrecting the Mysteries of Big Tau. Trends Neurosci. 2020;43(7):493–504. doi: 10.1016/j.tins.2020.04.007
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy. 2016;8(9):1119–1134. doi: 10.2217/imt-2016-0019
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M. The challenges of anti-tau therapeutics in Alzheimer disease. Nat Rev Neurol. 2022;18(10):577–578. doi: 10.1038/s41582-022-00702-0
   PubMed Web of Science ®Google Scholar
• Lozupone M, Dibello V, Sardone R, et al. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. Expert Opin Drug Discov. 2023;18(5):515–526. doi: 10.1080/17460441.2023.2200245
   PubMed Web of Science ®Google Scholar
• Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9–21. doi: 10.1038/nrneurol.2017.148
   PubMed Web of Science ®Google Scholar
• Frisardi V, Solfrizzi V, Capurso C, et al. Aluminum in the diet and Alzheimer’s disease: from current epidemiology to possible disease-modifying treatment. J Alzheimers Dis. 2010;20(1):17–30. doi: 10.3233/JAD-2010-1340
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21. doi: 10.1056/NEJMoa2212948
   PubMed Web of Science ®Google Scholar
• Eli Lilly press release. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional
   Google Scholar
• Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016;138(Suppl 1):211–221. doi: 10.1111/jnc.13640
   PubMed Web of Science ®Google Scholar
• Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–473. doi: 10.1212/WNL.57.3.467
   PubMed Web of Science ®Google Scholar
• Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–74. doi: 10.1016/j.jalz.2009.04.1231
   PubMed Web of Science ®Google Scholar
• Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15(1):84–87. doi: 10.1097/01.JGP.0000231744.69631.33
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883–2885. doi: 10.2147/NDT.S94430
   PubMed Web of Science ®Google Scholar
• Li Y, Hai S, Zhou Y, et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev. 2015;3(3):CD009444. doi: 10.1002/14651858.CD009444.pub3
   Google Scholar
• O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147–168. doi: 10.1177/0269881116680924
   PubMed Web of Science ®Google Scholar
• Yokoyama JS, Karch CM, Fan CC, et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017;133(5):825–837. doi: 10.1007/s00401-017-1693-y
   PubMed Web of Science ®Google Scholar
• Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006;63(10):1459–1467. doi: 10.1001/archneur.63.10.1459
   PubMedGoogle Scholar
• Paholikova K, Salingova B, Opattova A, et al. N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J Alzheimers Dis. 2015;43(3):915–926. doi: 10.3233/JAD-140996
   PubMed Web of Science ®Google Scholar
• Kontsekova E, Zilka N, Kovacech B, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer‘s disease model. Alzheimers Res Ther. 2014;6(4):44. doi: 10.1186/alzrt278
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer‘s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123–134. doi: 10.1016/S1474-4422(16)30331-3
   PubMed Web of Science ®Google Scholar
• Panza F, Logroscino G. Anti-tau vaccine in Alzheimer‘s disease: a tentative step. Lancet Neurol. 2017;16(2):99–100. doi: 10.1016/S1474-4422(16)30340-4
   PubMed Web of Science ®Google Scholar
• Shoeibi A, Olfati N, Litvan I. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. Expert Opin Investig Drugs. 2018;27(4):349–361. doi: 10.1080/13543784.2018.1460356
   PubMed Web of Science ®Google Scholar
• Song C, Shi J, Zhang P, et al. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond. Transl Neurodegener. 2022;11(1):18. doi: 10.1186/s40035-022-00292-3
   PubMed Web of Science ®Google Scholar
• Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399–415. doi: 10.1038/s41582-018-0013-z
   PubMed Web of Science ®Google Scholar
• Ayalon G, Lee SH, Adolfsson O, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease. Sci Transl Med. 2001;13(593):eabb2639. doi: 10.1126/scitranslmed.abb2639
   Google Scholar
• Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2022;79(8):758–767. doi: 10.1001/jamaneurol.2022.1375
   PubMed Web of Science ®Google Scholar
• Lananna BV, McKee CA, King MW, et al. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis. Sci Transl Med. 2020;12(574):eaax3519. doi: 10.1126/scitranslmed.aax3519
   PubMed Web of Science ®Google Scholar
• Lee SH, Le Pichon CE, Adolfsson O, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16(6):1690–1700. doi: 10.1016/j.celrep.2016.06.099
   PubMed Web of Science ®Google Scholar
• Roberts M, Sevastou I, Imaizumi Y, et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease. Acta Neuropathol Commun. 2020;8(1):13. doi: 10.1186/s40478-020-0884-2
   PubMed Web of Science ®Google Scholar
• Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-β production. Neurobiol Aging. 2015;36(2):693–709. doi: 10.1016/j.neurobiolaging.2014.09.007
   PubMed Web of Science ®Google Scholar
• Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo- controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549–558. doi: 10.1016/S1474-4422(19)30139-5
   PubMed Web of Science ®Google Scholar
• Dam T, Boxer AL, Golbe LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451–1457. doi: 10.1038/s41591-021-01455-x
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182–192. doi: 10.1016/S1474-4422(20)30489-0
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz F, Turton M, Kac PR, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration. Brain. 2023;146(3):1152–1165. doi: 10.1093/brain/awac407
   PubMed Web of Science ®Google Scholar
• Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, et al. Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci. 2014;34(12):4260–4272. doi: 10.1523/JNEUROSCI.3192-13.2014
   PubMed Web of Science ®Google Scholar
• Asuni AA, Boutajangout A, Quartermain D, et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27(34):9115–9129. doi: 10.1523/JNEUROSCI.2361-07.2007
   PubMed Web of Science ®Google Scholar
• Congdon EE, Gu J, Sait HB, et al. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 2013;288(49):35452–35465. doi: 10.1074/jbc.M113.491001
   PubMed Web of Science ®Google Scholar
• Collin L, Bohrmann B, Göpfert U, et al. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain. 2014;137(pt 10):2834–2846. doi: 10.1093/brain/awu213
   PubMed Web of Science ®Google Scholar
• McEwan WA, Falcon B, Vaysburd M, et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci, USA. 2017;114(3):574–579. doi: 10.1073/pnas.1607215114
   PubMed Web of Science ®Google Scholar
• Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–684. doi: 10.1016/S1474-4422(16)00070-3
   PubMed Web of Science ®Google Scholar
• Chai X, Wu S, Murray TK, et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem. 2011;286(39):34457–33467. doi: 10.1074/jbc.M111.229633
   PubMed Web of Science ®Google Scholar
• d’Abramo C, Acker CM, Jimenez H, et al. Passive immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies. PLoS One. 2015;10(8):e0135774. doi: 10.1371/journal.pone.0135774
   PubMed Web of Science ®Google Scholar
• Horie K, Barthélemy NR, Sato C, et al. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain. 2021;144(2):515–527. doi: 10.1093/brain/awaa373
   PubMed Web of Science ®Google Scholar
• Lozupone M, Imbimbo BP, Balducci C, et al. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer’s disease? Alzheimers Dement. 2023;19(1):353–368. doi: 10.1002/alz.12728
   PubMed Web of Science ®Google Scholar
• Pilowsky PM, Suzuki S, Minson JB. Antisense oligonucleotides: a new tool in neuroscience. Clin Exp Pharmacol Physiol. 1994;21(12):935–944. doi: 10.1111/j.1440-1681.1994.tb02655.x
   PubMed Web of Science ®Google Scholar
• Jabbari E, Duff KE. Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med. 2021;27(8):1341–1342. doi: 10.1038/s41591-021-01465-9
   PubMed Web of Science ®Google Scholar
• Moore EE, Gifford KA, Khan OA, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer’s disease. Alzheimers Dement. 2020;16(6):883–895. doi: 10.1002/alz.12087
   PubMed Web of Science ®Google Scholar
• Barthélemy NR, Horie K, Sato C, et al. Blood plasma phosphorylated- tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2000;217(11):e20200861. doi: 10.1084/jem.20200861
   Google Scholar